Synopsis:- A Noida-based condom manufacturer used an investor presentation ahead of a PhillipCapital conference to lay out an aggressive growth pitch built on export expansion, a newer female condom product line, and UN procurement qualification, alongside a long-term ambition of over Rs. 1,000 crore in revenue. The targets sit well ahead of the company’s current scale, and working capital metrics suggest the cash side of the business hasn’t kept pace with reported profit.
A Noida-based manufacturer of condoms and sexual wellness products is drawing investor attention ahead of an appearance at the “India Inc. Unplugged” investor conference today, after filing its presentation through a Regulation 30 disclosure to the NSE. The bulk of the document is forward-looking, built around export contracts, a female condom opportunity, and a long-term revenue ambition that dwarfs the company’s current size.
With a market capitalization of Rs.2,157.64 crore, the shares of Anondita Medicare were trading at Rs. 1,192.95, up 1.77 percent from its previous close of Rs.1,172.25.
Export Push and UN Qualification
The clearest near-term catalyst is exports. The company recently secured its first export order under a South African government condom tender, worth approximately Rs. 43.14 crore for 50 containers, with execution due by September 30, 2026. It has also received SABS certification for natural rubber latex condoms, opening access to South African and broader African institutional tenders, and has entered into a supply agreement in Kenya, with trial orders already placed.
The company says it is in advanced stages of UN qualification, which would open access to large-volume donor and government procurement channels such as UNFPA, and is targeting an export contribution of 25 percent of revenue by FY27, against a base where exports are currently a small fraction of the business.
Capacity Expansion
Manufacturing capacity has scaled quickly: installed capacity rose from 5,620 lakh pieces in FY25 to 8,690 lakh pieces in FY26, with an additional 307 million pieces added only in February 2026, meaning FY26 numbers reflect just 8-10 percent utilisation of that incremental capacity. The company has also expanded its Noida facility footprint by acquiring adjacent units (D2 and D3), with an estimated project cost of roughly Rs. 75 crore funded through a mix of internal accruals, debt, and equity issuance.
Beyond volume, the more interesting strategic angle is the female condom business, where the company says it has completed successful trial production and cites significantly higher margin potential, roughly 30-40 percent above male condoms, in a category served by very few global manufacturers. Management’s own roadmap, however, pushes full commercial female condom manufacturing out to 2027, with non-latex products and a captive latex plantation initiative not contemplated until 2028-2029, so the near-term revenue contribution from this segment should be treated as limited.
An Aggressive Long-Term Number Worth Sizing Against Current Scale
The presentation’s most striking figure is a stated long-term ambition of over Rs. 1,000 crore in total projected revenue, alongside a nearer-term FY27 target of 60-70 percent revenue growth with EBITDA margins around 30 percent. Both numbers deserve context. FY26 revenue came in at Rs. 137 crore, so the Rs. 1,000 crore figure represents roughly a 7x scale-up with no stated timeline attached in this document, making it better read as a long-term aspiration than a guided target.
The nearer-term margin target is also worth flagging: the company’s FY26 consolidated EBITDA margin was already 37 percent, comfortably above the 30 percent figure management is now guiding toward for FY27, which suggests margin dilution is expected as the company leans further into lower-margin export tenders and institutional procurement, even as volumes grow.
Working Capital Is the Number to Watch
Despite the profit growth, the balance sheet shows some strain points common to fast-scaling small caps. Debtor days rose from 127 to 138 over the year, and the cash conversion cycle, while improving slightly, remains stretched at over 215 days. Operating cash flow turned positive at Rs. 11 crore for the year, an improvement from the prior year’s negative figure, but this still sits well below the Rs. 34 crore in reported net profit, a gap worth monitoring as the company takes on more government and export-tender business, where payment cycles can run long.
Promoters also secured shareholder approval in May for warrants and related-party transactions, alongside management pay increases, which is standard for a growth-stage company but worth knowing before reading the rest of the growth narrative.
FY26 Results
For the year, consolidated revenue rose to Rs. 137.42 crore from Rs. 77 crore in FY25, with EBITDA more than doubling to roughly Rs. 51 crore and net profit rising to Rs. 34.30 crore. The second half of the year was notably stronger than the first, with H2 EBITDA margin at 38.3 percent against 35 percent in H2 FY25.
Anondita Medicare Limited, incorporated in 2024 but built on a manufacturing business going back to 1999, makes male and female condoms under the COBRA brand from its Noida, Uttar Pradesh facility, alongside surgical gloves and pregnancy test kits, distributing through a network of super stockists, distributors, and retailers concentrated in North India.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
